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Human papillomavirus type 16 (HPV16) infections are intra-epithelial, and thus, HPV16 is known to
interact with Langerhans cells (LCs), the resident epithelial antigen-presenting cells (APCs). The current
paradigm for APC-mediated induction of T cell anergy is through delivery of T cell receptor signals via
peptides on MHC molecules (signal 1), but without costimulation (signal 2). We previously demonstrated
that LCs exposed to HPV16 in vitro present HPV antigens to T cells without costimulation, but it remained
uncertain if such T cells would remain ignorant, become anergic, or in the case of CD4þ T cells, differ-
entiate into Tregs. Here we demonstrate that Tregs were not induced by LCs presenting only signal 1, and
through a series of in vitro immunizations show that CD8þ T cells receiving signal 1þ2 from LCs weeks
after consistently receiving signal 1 are capable of robust effector functions. Importantly, this indicates
that T cells are not tolerized but instead remain ignorant to HPV, and are activated given the proper
signals.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human papillomavirus (HPV) affects millions of individuals
worldwide as it is causally linked to the development of cervical,
vaginal, anal, and head and neck cancers [1–5]. Of the oncogenic
high-risk HPV (hr-HPV) genotypes, HPV type 16 (HPV16) is the
most common and accounts for more than 50% of all cervical
cancers and 90% of HPV-related head and neck squamous cell
carcinomas [6–9]. Various studies have found that HPV capsids,
also known as virus-like particles (VLPs), can bind to and stimulate
the activation of dendritic cells (DCs) in vitro [10–13], providingB.V. This is an open access article u
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ast).evidence that they can induce the maturation of antigen-
presenting cells (APCs), which could in turn mediate adaptive
immune responses. Despite the ability of HPV capsid proteins to
initiate immune responses in human DCs in vitro, more than 15% of
women that have hr-HPV infections do not initiate effective
immune responses against HPV, and among those that do, viral
clearance is slow with an average time of 8–16 months [14–18],
indicating that HPV is escaping immune detection in vivo.
How HPV infection remains undetected by the immune system,
and what cells and cellular mechanisms are involved have been
central questions to our research. Through multiple prior investi-
gations, we have demonstrated that HPV-mediated manipulation
of Langerhans cell (LC) immune function is a key mechanism by
which HPV evades immune detection [19–23]. LCs are the resident
professional APCs of the mucosal epithelial layer that account for
roughly one in twenty cells of the epithelium [24], and are
responsible for initiating immune responses against skin invading
viruses [25]. However, our group has demonstrated that HPV16
manipulates human LCs in such a manner that internalization of
HPV16 VLPs into LCs results in suppressive signaling and defective
activation, which differs from human DC responses [26,27]. When
stimulated with HPV16 VLPs, the mitogen-activated protein kinasender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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LCs. Conversely, HPV16 VLP exposure of LCs initiates a signaling
cascade that activates the phosphoinositide 3-kinase (PI3K) path-
way, yet inactivates Akt [19]. The phenotypic consequence of this
is that LCs exposed to HPV16 VLPs in vitro are able to present HPV
antigens in the absence of costimulation [28]. The lack of costi-
mulation by LCs may be one reason that T cell immunity is lacking
in those with persistent HPV infections (reviewed in [29]).
According to current textbook understanding, the presentation
of antigens on major histocompatability complex (MHC) molecules
to T cell receptors (TCR) (providing signal 1) by APCs without the
concurrent presentation of costimulatory molecules (providing
signal 2) induces T cell anergy or tolerance [30–32]. Alternatively,
T cells can remain in an ignorant state with the ability to respond
to antigens upon future encounters. Costimulatory molecule
recognition by their corresponding receptor on T cells, i.e. CD80 or
CD86 by CD28, was proposed by early studies to be essential for
the prevention of clonal anergy of CD4þ T cells either through
direct inhibition on the production and function of anergic factors,
[33] or indirectly through cell-cycle effects via stimulation of IL-2
[34,35]. There has been signiﬁcant experimental evidence to
support the latter hypothesis involving IL-2 stimulation (reviewed
in [36,37]). Similarly, the original demonstration of induced anergy
of CD8þ T cells by APCs lacking costimulatory molecules was made
in CD8þ clones where the phenotype was described as inhibition
of IL-2 production and proliferation, though less effect on inter-
feron gamma (IFN-γ) production or cytotoxic activity was
observed [38]. Despite the apparent retention of cytotoxic activity
in tolerized CD8þ T cells, the lack of clonal expansion hinders any
measurable adaptive immune response.
Naïve CD4þ T cells play a key role in effective anti-tumor
immunity and may differentiate into effector or regulatory subsets
depending on the stimulus received from APCs. Beyond anergic
CD4þ T cells, recent studies have shown a signiﬁcant role for
regulatory T cells (Tregs) in the development of HPV-associated
malignancies and these cells are found in high frequencies in
cervical intraepithelial neoplastic (CIN) lesions [39–42]. Tregs are
suppressive T cells that inhibit the proliferation and activation of
effector T cells to prevent an autoimmune attack [43]. Naïve CD4þ
T cells can differentiate into regulatory subsets when costimula-
tory molecules from immature DCs are lacking; however, this has
not been investigated for LCs. Tregs may be expanded from a naïve
population after exposure to HPV16-presenting LCs, which could
be an additional HPV escape mechanism. Hence, the differentia-
tion of CD4þ T cells into Tregs, Th1, or Th2 cells after incubation
with HPV16-exposed LCs was explored in this study.
The absence of T cell immunity during persistent HPV infec-
tions may be a direct result from the lack of APC costimulation.
However, studies have not yet explored the resultant phenotypes
of CD4þ or CD8þ T cells after incubation with LCs presenting HPV
antigens in the absence of costimulation, which was a focus of the
current study. Hence, the fate of CD4þ and CD8þ T cells exposed
to potentially tolerizing LCs that express HPV antigens without
signal 2 was investigated to determine whether the resultant T
cells were irreversibly tolerized, ignorant to HPV antigens, or in
the case of CD4þ T cells, became Tregs. Additionally, we deter-
mined whether toll-like receptor (TLR) agonist-matured LCs pre-
senting proper signal 1 and signal 2 stimuli could restore CD8þ T
cell cytotoxic activity against HPV16 antigens after long-term
exposure to LCs providing only signal 1.2. Materials and methods
2.1. Donor material
Peripheral blood mononuclear cells (PBMCs) were isolated
from healthy donors via leukapheresis. PBMCs were subsequently
puriﬁed over lymphocyte separation medium (Cellgro, Manassas,
VA), cryopreserved, and stored in liquid nitrogen [22]. Donor
PBMCs were HLA-A and HLA-DR typed. Low-resolution DNA typ-
ing for HLA-A2 was performed using standard endpoint PCR,
which was conﬁrmed by ﬂow cytometry using an anti-HLA-A2
antibody (BD Biosciences, San Jose, CA). For HLA-A2þ samples,
high-resolution genotyping was performed at the HLA-A2 locus
with the A*02 SSP UniTray Kit (Life Technologies, Carlsbad, CA).
HPV serology was negative for all donors. All protocols were
approved by the University of Southern California's Institutional
Review Board, and informed consent was obtained from
each donor.
2.2. Antibodies and reagents
The following antibodies were purchased from BD Biosciences:
CD4 FITC, CD4 PE, HLA-ABC FITC (MHC I), HLA-DP,DQ,DR FITC
(MHC II), CD80 FITC, and CD86 FITC. The following antibodies were
purchased from Biolegend (San Diego, CA): CD4 PC5, CD4 PC7,
CD45RA FITC, IFN-γ PC7, IL-10 PE, IL-4 FITC, and CD25 PE. The
following antibody was purchased from eBioscience (San Diego,
CA): Foxp3 FITC. Appropriate isotype controls were purchased
from either BD Biosciences or Biolegend. Human IFN-γ capture
and detection antibodies were purchased from Mabtech (Cincin-
nati, OH). Poly-ICLC (Hiltonol) is a clinical grade current good
manufacturing practices (cGMP) poly-lysine stabilized form of
Poly polyinosinic-polycytidylic acid (PolyIC) provided by Oncovir,
Inc. (Washington, D.C.).
2.3. Primary cell culture and LC generation
PBMC monocyte-derived LCs were generated following pub-
lished procedures [44,45]. Frozen PBMCs were thawed and washed
once in complete medium: RPMI 1640 (Life Technologies) con-
taining 10 mM sodium pyruvate (Life Technologies), 10 mM non-
essential amino acids (Life Technologies), 100 mg/ml kanamycin
(Sigma-Aldrich, St. Louis, MO), 50 mM β-Mercaptol Ethanol (Life
Technologies), and 10% FBS (Omega Scientiﬁc, Tarzana, CA). PBMCs
were plated in a 175-cm2 tissue culture ﬂask for 2 h at 37 °C.
Nonadherent primary cells were then washed off and remaining
adherent monocytes were cultured for 7 days in complete medium
containing 1000 U/ml rhGM-CSF (Genzyme, Boston, MA), 1000 U/
ml rhIL-4 (Life Technologies), and 10 ng/ml rhTGF-β1 (Life Tech-
nologies). Cytokines were replenished on days 3 and 6. LC pheno-
type in the resultant cells containing the hallmark Birbeck granule
structures was conﬁrmed as LangerinþCD1aþE-Cadherinþ (data
not shown), as previously demonstrated [23].
2.4. Chimeric virus like particles
HPV16 L1L2 VLPs and HPV16 L1L2E7 chimeric VLPs (cVLPs)
were generated in insect cells and puriﬁed by sucrose and cesium
chloride ultracentrifugation as previously described [46], and
endotoxin levels were measured below 0.06 EU using an E-toxate
kit (Sigma-Aldrich). Western blot analysis conﬁrmed the presence
of E7, L1, and L2 proteins. Transmission electron microscopy was
used to validate intact VLP and cVLP structure.
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LCs were treated with HPV16 VLPs only or treated with HPV16
VLPs for 4 h before stimulation with Poly-ICLC, a TLR3 agonist that
has been shown to effectively activate LCs [47,48], and activation-
associated surface markers were measured by ﬂow cytometry
following established procedures [45]. In brief, 106 LCs were see-
ded in a 6-well plate and left untreated, treated with 20 μg HPV16
VLPs, or 20 μg HPV16 VLPs for 4 h followed by 72 h incubation
with Poly-ICLC. Cells were harvested, washed, stained for surface
MHC I, MHC II, CD80, CD86, or isotype controls, and analyzed on
an FC500 ﬂow cytometer using CXP software (Beckman Coulter,
Brea, CA). Geometric mean ﬂuorescence intensities (MFI) were
used to calculate fold change in expression from untreated LC
baseline values.
2.6. CD4þ in vitro immunization (IVI) assay and phenotyping
LCs from HLA-A*0201þ donors and autologous CD4þ T cells
were co-cultured in vitro over several weeks to evaluate T cell
phenotypes following established procedures [49]. Speciﬁcally, LCs
were either left untreated or treated with HPV16 L1L2E7 cVLPs for
1 h at 37 °C, and then medium was supplemented with 1000 U/ml
of rhGM-CSF and LCs were incubated for an additional 4 h. LCs
were then cultured with or without Poly-ICLC for 20 h at 37 °C. As
a positive control, LCs treated with Poly-ICLC were peptide pulsed
with HLA-A2 restricted E7 peptides (E71–12, E748–62 and E762–75)
[50,51]. All LC groups were subsequently irradiated (30 Gy).
Autologous Naïve CD4þ T cells were isolated using a negative
Magnetic Cell Separation Kit (Miltenyi Biotec, Auburn, CA) and
5105 cells/well were seeded in a 48-well plate and were co-
cultured with 2.5104 irradiated LCs. Additional treated and
irradiated LCs were added on day 7, 14, and 21 at the same T cell to
LC ratio (20:1). Culture medium was supplemented with IL-10
(10 ng/ml) 24 h after each LC addition, and supplemented with IL-
2 (50 U/ml) 48 and 96 h after each LC addition. On day 28, CD4þ T
cells were collected from each group and assessed for phenotypic
T cell markers via ﬂow cytometry. Single cell suspensions of CD4þ
T cells were washed and subsequently stained for surface marker
expression following manufacturer instructions for each antibody.
Cells that required permeabilization for intracellular staining were
ﬁxed and permeabilized (FoxP3 kit, eBioscience) overnight and
stained the following day. Cells were analyzed by ﬂow cytometry
as described above.
2.7. CD8þ IVI and ELISpot assay
LCs and autologous puriﬁed CD8þ T cells and were co-cultured
in vitro over several weeks to induce primary CD8þ effector T cell
responses against deﬁned HLA-A*0201 HPV16 E7 epitopes fol-
lowing published protocols [49]. Speciﬁcally, LCs were treated and
irradiated as described above in the CD4þ IVI assay. Autologous
CD8þ T cells were isolated from cryopreserved PBMCs using a
negative Magnetic Cell Separation Kit (MACS by Miltenyi). 5105
CD8þ T cells were then co-cultured with irradiated LCs (2.5104
cells/well). Additional irradiated LCs were added on day 7 as
described above. By day 14, non-proliferative, unresponsive CD8þ
T cells were generated by HPV16 cVLP-exposed LCs, while pro-
liferative, activated CD8þ T cells were generated with exposure to
Poly-ICLC-treated and peptide pulsed LCs. On day 14 and 21, LC
additions were altered such that non-proliferative CD8þ T cells
were given peptide pulsed LCs and activated CD8þ T cells were
given HPV16 cVLP-exposed LCs. Co-culture medium was supple-
mented with IL-7 (10 ng/ml) within 24 h of LC additions. Culture
medium was supplemented with IL-10 (10 ng/ml) 24 h after each
LC addition, and supplemented with IL-2 (50 U/ml) 48 and 96 hafter each LC addition. 96-well ELISpot plates (Millipore Multi-
screen HTS IP; Millipore, Temecula, CA) were coated with IFN-γ
capture antibody (Mabtech mouse anti-human IFN-γ, Clone
1-D1K) in PBS overnight at 4 °C and plates were blocked with
complete medium. CD8þ T cells (1106 cells/ml) with HLA-A2
binding E7 peptides or media only (2 mg/ml) were seeded on the
ELISpot plate in quadruplicates and incubated overnight at 37 °C.
After 24 h, plates were washed and incubated with IFN-γ detection
antibody (Mabtech mouse anti-human IFN-γ biotin, Clone 7-B6-1)
for 2 h followed by streptavidin-horse radish peroxidase (Sigma-
Aldrich) for 1 h at room temperature. Plates were then developed
with 3-amino-9-ethyl-carbazole (Sigma-Aldrich) substrate for 5 m,
and spots were counted using the KS ELISpot analysis system
(Carl Zeiss, Thornwood, NY), and the number of spots in media
only containing wells was subtracted from HPV E7 peptide con-
taining wells to determine the number of spots above background.
2.8. Cytokine and chemokine analysis
Supernatants were collected from LC cultures on day 3 and
CD4þ IVI cultures on day 14 and subjected to a multiplex enzyme
linked immunosorbent assay (ELISA) for cytokine and chemokine
analysis. The experiment was performed using a Millipore Milli-
plex Human Cytokine Kit and the Bio-Plex Suspension Array Sys-
tem (Bio-Rad, Irvine, CA).
2.9. Statistical analysis
All statistical analyses were performed on Graphpad Prism
version 5.0 (GraphPad Software Inc., San Diego, CA). Statistical
signiﬁcance for ELISpot and cytokine results were assessed with a
two-tailed t-test comparing data to negative controls. Signiﬁcance
was deﬁned at po0.05 for all experiments.3. Results
3.1. HPV16-exposed LCs present antigen without costimulation
Immature LCs express lower, albeit substantial, levels of MHC
class I and class II molecules than activated LCs, but exhibit little to
no expression of CD80 and CD86 costimulatory molecules (Fig. 1).
Upon treatment of LCs with HPV16 alone, the expression of these
markers did not change, demonstrating a lack of phenotypic
activation. Interestingly, we have previously demonstrated that
similarly treated DC become activated [22], indicating a unique
manipulation of LC by HPV16. More importantly, this shows the
ability of LCs to present antigen without costimulation, which is in
agreement with our previous results that demonstrated that
HPV16-treated LCs could speciﬁcally present HPV antigens with-
out signal 2 [28]. Conversely, LCs stimulated with the TLR3 agonist
Poly-ICLC both alone and after HPV16 exposure showed a sig-
niﬁcant increase in the expression of antigen presentation and
costimulatory molecules, which are the hallmarks of activated LCs
that provide both signal 1 and 2.
3.2. HPV16-exposed LCs do not secrete pro-inﬂammatory cytokines
Since anti-viral CD8þ T cell induction requires APCs to secrete
pro-inﬂammatory cytokines and chemokines, the secretion of
various inﬂammatory cytokines and chemokines by LCs after
exposure to HPV16 alone or followed by activation with poly-ICLC
was assessed. LCs that were pre-exposed to HPV16 showed no
increase in cytokine production (Fig. 2), whereas LC activation by
poly-ICLC, whether or not in the presence of HPV16, induced
Fig. 1. HPV16-exposed LCs present antigen without costimulation. LC surface marker expression of antigen presentation and costimulatory molecules was evaluated via ﬂow
cytometry. LC were left untreated or treated with HPV16 VLP, Poly-ICLC, or HPV16 VLP prior to Poly-ICLC. Average mean ﬂuoresence intensity (MFI) of surface marker
staining7SD is shown (n¼4; **po0.01 and ***po0.001 compared to untreated). A. Representative histograms, and B. Each graph is representative of at least four inde-
pendent experiments.
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turn activate T cells after antigen presentation.
3.3. Activated LCs induce activated CD4þ T cells from naïve CD4þ T
cell populations
The phenotypic characteristics of CD4þ T cells after exposure to
HPV16-presenting LCs with and without costimulation had pre-
viously been unknown. Here, the fate of naïve CD4þ T cells, isolated
based on CD4 and CD45RA expression, was determined subsequent
to co-culture with either immature (lacking signal 2) or mature LCs
(with signal 2) in an IVI assay. Naïve CD4þ T cells were co-cultured
with either medium (no LCs), untreated LCs, peptide pulsedþPoly-
ICLC-treated LCs, HPV16 cVLP-exposed LCs, or HPV16 cVLPþPoly-
ICLC-treated LCs for four consecutive weeks, with additional LCs
exposed in the same manner added each week. We then phenotyped
the resultant CD4þ T cells for surface and intracellular makers via
ﬂow cytometry. Exposure of naïve CD4þ T cells to untreated LCs or
HPV16 cVLP-exposed LCs resulted in a high frequency of remaining
naïve CD4þ T cells and a low frequency of induced effector CD4þ T
cells compared to those exposed to activated LCs, as demonstrated by
the co-expression of CD4 and CD45RA, a marker for naïve T cells
(Fig. 3A). Conversely, exposing naïve CD4þ T cells to activated LCs,
including peptide pulsedþPoly-ICLC-treated LCs and HPV16
cVLPþPoly-ICLC-treated LCs, caused a complete depletion of the
naïve CD4þ T cell population (Fig. 3A) and a higher frequency of
induced effector CD4þ T cells, as demonstrated by increased
expression of the activation marker CD25 (Fig. 3B).
3.4. HPV16-exposed LCs do not induce Tregs from a naïve CD4þ T
cell population
While it has been reported that CIN and cervical cancer patients
have an increased frequency of Tregs in the cervix [41,42], it was not
known whether these Tregs were induced from naïve CD4þ T cellsencountering HPV16-exposed LCs providing only signal 1. As imma-
ture LCs could potentially have tolerizing abilities, it was hypothe-
sized that naïve CD4þ T cells could differentiate into a regulatory
phenotype when co-cultured with LCs in the absence of costimula-
tion. Therefore, we assessed the Treg induction through immuno-
phenotyping after naïve CD4þ T cell exposure to differentially acti-
vated LCs. Speciﬁcally, CD4þ T cells were analyzed for CD4 and CD25
cell surface markers, and for the Treg intracellular marker, FoxP3. LCs
presenting only signal 1 were expected to generate an increased
frequency of Tregs due to the lack of costimulation. Interestingly, we
observed that co-culture of naïve CD4þ cells with either immature or
mature LCs did not signiﬁcantly affect the frequency of Tregs, and
their frequency was approximately only 1% of any of the co-culture
groups (Fig. 4). Although the literature suggests a signiﬁcant role for
Tregs in HPV-induced malignancies, the lack of costimulation from
immature HPV16-exposed LCs did not to lead to an induction of
Tregs from a naïve CD4þ T cell population.
3.5. CD4þ T cells produce increased levels of IL-10 when co-cultured
with HPV16-exposed LCs
A multiplex-ELISA was performed to investigate whether CD4þ
T cells secrete Th1, Th2, or Treg associated cytokines after exposure
to differentially activated LCs. This analysis was performed on day
14 supernatants of each study arm of the IVI. Exposure of CD4þ T
cells to activated LCs (either peptide pulsedþPoly-ICLC or HPV16
cVLPþPoly-ICLC treated LCs) induced the secretion of Th1- and
Th2-associated cytokines. Most notably, these included the Th1-
associated cytokines IFN-γ and TNF-α, and the Th2-associated
cytokines IL-4 and IL-5 (Fig. 5). There was no difference in the
levels of the Treg-promoting cytokine TGF-β in any treatment
group (data not shown), which is in agreement with the above
results with the same low frequency of Tregs in each study arm
(Fig. 4). Surprisingly, the inhibitory cytokine IL-10 was elevated in
T cells co-cultured with immature LCs lacking costimulation
Fig. 2. HPV16-exposed LCs do not produce high levels of inﬂammatory cytokines and chemokines. LCs were left untreated or treated with HPV16 VLP, Poly-ICLC, or HPV16
VLP prior to Poly-ICLC. Cell supernatants were analyzed for a panel of 9 cytokines and chemokines using a Bio-Plex Suspension Array System. Data represent the mean7SD
analyte concentration (n¼3; ***po0.001 compared to untreated). Each graph is representative of at least four independent experiments.
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from cells co-cultured with activated LC. These data highlight the
importance of activated LCs in an HPV setting to promote Th1-
differentiation, which is advantageous for effective viral clearance.
3.6. CD8þT cells are not tolerized by HPV16-exposed LCs in the
absence of costimulation
HPV16-exposed LCs are not phenotypically or functionally acti-
vated as shown above (Figs. 1 and 2), and as such we have previouslydemonstrated that these LCs do not induce HPV16-speciﬁc CD8þ T
cell responses despite HPV antigen presentation [23,28,44]. However,
it was uncertain if these LCs induced T cell anergy or if the CD8þ T
cells remained ignorant, which was a focus of the current study.
Here, we incubated naïve CD8þ T cells with either HPV16-exposed
LCs providing only signal 1, or activated LCs providing both signal
1 and 2. Our results demonstrate that unresponsive (non-pro-
liferative and lacking IFN-γ secretion) CD8þ T cells were generated
by co-culturing naïve CD8þ T cells for 14 days with HPV16-exposed
LCs that lack costimulatory molecule expression (Fig. 6A), although it
Fig. 3. Activated LCs induce activated CD4þ T cells from naïve CD4þ T cell populations. (A) CD4þ T cells were analyzed via ﬂow cytometry for CD4 and CD45RA surface
markers representing the naïve CD4þ T cell population subsequent to CD4þ IVI. Naïve CD4þ T cells were co-cultured with differentially treated LC as indicated by the
following treatments for 4 weeks: medium, untreated LC, peptide pulsed and Poly-ICLC activated LC, HPV16 cVLP-exposed LC, or HPV16 cVLP-exposed and Poly-ICLC-
activated LC. The frequency of CD4þCD45RAþ T cells are indicated. (B) Frequency of CD4þCD25þ cells are indicated that represent the percentage of activated CD4þ T cells.
All experiments were repeated three times in different donors and representative data are shown.
Fig. 4. HPV16-exposed LCs do not induce Tregs from a naïve CD4þ T cell population. CD4þ T cell populations were analyzed for the presence of Tregs. The percentage of
CD25þFoxP3þ T cells (Tregs) are shown (upper right quadrant). All experiments were repeated for three different donors and representative data are shown.
Fig. 5. CD4þ T cells produce increased levels of IL-10 when co-cultured with HPV16-exposed LCs. Cytokine proﬁles of CD4þ T cells co-cultured with differentially treated LC
are presented. The different treatment groups are shown for each cytokine presented. The experiment was repeated for three different donors and representative data are
shown as the mean7SD (*po0.05 and ***po0.001 compared to untreated).
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thereafter. This was in contrast to naïve CD8þ T cells co-cultured
with activated LCs (peptide pulsed and Poly-ICLC treated), which
exhibited a robust HPV16-speciﬁc response in the same time period.A vital question that remained was if T cells co-cultured with
the HPV16-exposed LCs (displaying signal 1 only) were tolerized to
HPV16 antigens. To investigate this, the day 14 unresponsive CD8þ
T cells were co-cultured with peptide pulsed Poly-ICLC-activated
Fig. 6. CD8þT cells are not tolerized by HPV16-exposed LCs in the absence of costimulation. 14- and 28-day ELISpot results are presented. (A) The number of E7 speciﬁc IFNγ
producing CD8þ T cells per million T cells induced by stimulation of autologous CD8þ T cells with untreated, HPV16 cVLP-exposed, or E7 peptideþPoly-ICLC treated LC in
HLA-A*0201 positive patients after 14 days. Spots from no E7 peptide wells have been subtracted to display the number of peptide-speciﬁc T cells induced in each treatment
group above background levels. (B) T cells co-cultured with HPV16 cVLP-exposed LC for 14 days were either cultured with HPV16 cVLP exposed LC or E7 peptideþPoly-ICLC
treated LC for an additional 14 days. (C) T cells co-cultured with E7 peptideþPoly-ICLC treated LC for 14 days were either cultured with HPV16 cVLP exposed LC or E7
peptideþPoly-ICLC treated LC for an additional 14 days. Data are shown as the mean7SE of six separate experiments (*po0.05 and ***po0.001 compared to cVLP).
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that generated the unresponsive cells (Fig. 6B). We hypothesized
that if anergy occurred, then the T cells would be tolerant to
subsequent antigen delivery. Interestingly however, HPV-speciﬁc T
cell induction was increased in previously unresponsive T cells co-
cultured with HPV16-exposed LCs. This data suggests that these T
cells were not tolerized by LCs providing only signal 1, but were
rather ignorant to viral antigens. Lastly, it was unknown whether
HPV16-exposed LCs could functionally suppress active HPV-
speciﬁc CD8þ T cells. Therefore, we generated a population of
HPV16 E7-speciﬁc CD8þ T cells through co-culture with peptide
pulsed Poly-ICLC-activated LCs. These responsive HPV16-speciﬁc
CD8þ T cells were subsequently co-cultured with HPV16-exposed
LCs lacking costimulation, and their response to the E7 epitope
was assessed. Our results indicate that HPV-speciﬁc CD8þ T cells
continue to show immune responses against E7, but lack pro-
liferative ability without signal 2, as the number of total spots
increased to only a fraction of those with continual signal 1 and
2 stimulation (Fig. 6C). These results suggest that immature LCs
providing only signal 1 slow down or halt the adaptive immune
response such that no further clonal expansion occurs.4. Discussion
The phenotype of immature LCs derived from monocytes
in vitro has been deﬁned as high expression of MHC class I, class II,
and CD1a with low expression of the co-stimulatory molecules
and maturation markers CD40, CD80, CD83, CD86, and CCR7 [52].
Similar low levels of CD80 and CD86 were shown for immature
LCs isolated from skin in vivo [53], which was comparable to what
was observed herein. Upon proper pathogenic stimulation, LCs
undergo dramatic changes including the activation of signaling
cascades, the release of pro-inﬂammatory cytokines, and impor-
tantly, the up-regulation of co-stimulatory molecules [54–56].
In vivo, activated LCs then migrate to lymph nodes, processing viralantigens en route, where they interact with naïve T cell popula-
tions by presenting antigens (signal 1) with costimulation (signal
2) to initiate an adaptive T cell response [54,57]. Additionally, it has
been shown that LCs can spontaneously migrate [58,59], and thus
immature LCs undergoing spontaneous migration may present
antigens without signal 2, which may lead to T cell anergy or the
induction of Tregs. Activated effector CD8þ T cells migrate back to
the site of infection and destroy infected cells. However, with
regard to HPV infections, LCs from healthy donors exposed to
high-risk HPV strains do not become functionally mature APCs, but
can still spontaneous migrate [60]. Therefore, the focus of this
study was to investigate T cell subsets induced by these immature
LCs, as the phenotypes and functionality of T cells resulting from
co-culture with HPV16-exposed LCs in vitro had yet to be explored.
In the present study, we examined CD4þ and CD8þ T cell
subsets induced by HPV16-exposed LCs providing only signal 1,
and determined whether unresponsive CD8þ T cells encountering
these LC could regain cytotoxic functions after proper signal 1 and
2 stimulation. It is tacit that effective CD4þ and CD8þ T cell
responses play a crucial role in viral clearance and anti-tumor
immunity against HPV-induced malignancies. Importantly, our lab
has previously demonstrated that HPV16 evades the host immune
response by not activating LCs despite their presentation of HPV
antigens resulting in the absence of effector CD8þ T cells against
HPV antigens [23,26,44,61]. This process includes the dysregula-
tion of the PI3K-Akt signaling pathway and defective cellular
activation [23,26]. Accordingly, it is reasonable to hypothesize that
antigen presentation is also disrupted in these cells. However,
HPV16 E7-speciﬁc T cells can recognize and kill LCs exposed to
HPV16 cVLPs [28], indicating that LCs are able to effectively cross-
present HPV-derived peptides after cVLP internalization.
We have previously demonstrated that treatment with a TLR8
agonist can activate LCs, whereas a TLR7 agonist does not [44],
suggesting that the speciﬁc TLR molecule engaged on LCs has an
effect on the resulting immune response. More recently, we
demonstrated that TLR3 is expressed by monocyte-derived LCs,
A.W. Woodham et al. / Papillomavirus Research 2 (2016) 21–3028and that Poly-ICLC, a TLR3 agonist, is a potent activator of LC
[52,62]. While it was shown that some TLR agonists work syner-
gistically to increase cytokine production by APC, no increase was
observed on the expression of costimulatory molecules [63].
Moreover, overstimulation can lead to impaired APC function,
which decreases their ability to induce adaptive immune respon-
ses [64,65], and thus Poly-ICLC was chosen as the single potent LC
activating agent herein.
It has previously been concluded that the lack of responsive
cytotoxic CD8þ T cells against HPV16 is linked to the progression
of CIN lesions and persistence of HPV infection [66]. Here, we
demonstrate that co-culturing naïve CD8þ T cells with HPV16-
exposed immature LCs results in non-proliferative, unresponsive
CD8þ T cells, whereas co-culture with HPV peptide pulsed Poly-
ICLC-activated LCs results in a robust cytotoxic T cell response. In a
crossover design, we demonstrate that LCs providing proper signal
1 and 2 elicit functional effector properties against HPV antigens in
the unresponsive T cells, and this data suggests that CD8þ T cells
are ignorant rather than tolerant to HPV antigens after consistently
receiving signal 1 without signal 2. Furthermore, we demonstrated
that HPV16-exposed LCs lacking signal 2 essentially stopped sti-
mulating the previously activated T cells. Together, these results
indicate the importance of signal 2 in inducing functional activity
in evidently ignorant CD8þ T cells, and indicate a different fate
from the current paradigm of irreversible anergy caused by anti-
gen presentation in the absence of costimulation. These results
also imply that the development of new therapies to induce acti-
vation of HPV-exposed LCs may lead to potent CD8þ T cell
responses in vivo even after T cells have encountered HPV-16
exposed LC providing only signal 1.
Beyond CD8þ T cells, it was suspected that regulatory T cell
subsets may be induced by these immature HPV16-exposed LCs
from naïve CD4þ T cells based on the high frequency of Tregs seen
in the cervix of women with HPV-induced lesions [41,42,67,68].
The results of the current study demonstrate that Poly-ICLC-
activated and HPV16 exposed LCs induced effector CD4þ T cells
from a naïve CD4þ population, whereas HPV16-only-exposed LCs
were immature and induced few effector CD4þ T cells and like-
wise a higher proportion of the naïve CD4þ population remained
in these cultures. Contrary to our hypothesis, these HPV16-
exposed immature LCs did not induce Tregs. Furthermore, there
were no signiﬁcant differences in Tregs induced among any of the
study groups. Therefore, the source of the large quantity of Tregs
found in cervical cancer biopsies remains unknown, but suggests
that Tregs may be recruited into the tumor microenvironment
rather than being induced by HPV itself. Alternatively, suppressive
cytokines such as TGF-β and IL-10 may dictate the regulatory fate
of naïve CD4þ T cells in the cervix, which suggests that Tregs may
be induced by local stromal cells and not by immature LC.
While our results show that HPV16-exposed immature LCs did
not directly lead to Treg induction in vitro, these LCs did promote a
suppressive environment by mediating the secretion of the sup-
pressive cytokine IL-10 by co-cultured T cells, which can suppress
the differentiation of naïve T cells to effector cells. Our cytokine
analysis also showed that there was reduced secretion of Th1 and
Th2 cytokines (IL-4, IL-5, TNF-α, and IFN-γ) by T cells co-cultured
with the HPV16-exposed immature LCs. The IL-10 secretion by T
cells co-cultured with HPV16-exposed LC was similar to what was
observed when T cells were co-cultured with untreated LCs that
are expected to present self-antigens without costimulation. These
results may reﬂect a shift in the current LC paradigm. Once
thought that their primary function was to take up antigens
penetrating the epidermal layer and convey them to draining
lymph nodes where they display them in an immunogenic manner
to T cells, recent mouse studies suggest that LCs have naturally
immunosuppressive functions that can dampen T cell responses[69–74]. Despite this proposed suppressive role, human LCs have
been shown to be highly adept at class I-mediated antigen pro-
cessing, cross-presentation, and inducing primary CD8þ T cell
responses [75], and have a transcriptional signature similar to
murine dermal DC-speciﬁc subsets with similar cross-presenting
capabilities [76]. In light of the results herein, this may suggest
that immature human LCs residing in the epidermis presenting
self-antigens dampen cell-mediated immune responses, and this
natural suppressive ability is hijacked by HPV as it enters LCs
without activating them. Conversely, if these LCs later become
activated through proper stimulation, they are capable of inducing
robust Th1þ and CD8þ T cell responses.
Overall, our data indicate the importance of therapeutic adju-
vants like Poly-ICLC in restoring activity of LCs to educate CD4þ
and CD8þ T cells for an effective cell-mediated anti-HPV immune
response. Our results further indicate that the absence of costi-
mulation by immature LCs does not contribute to Treg induction in
the presence of HPV antigens, but does lead to the reduction of
essential Th1-associated cytokine secretion. Moreover, the induced
secretion of IL-10 in the unresponsive setting potentially pro-
hibited the induction of effector functions while maintaining
quiescence in the naïve CD4þ T cell population. In conclusion,
activated LCs presenting antigens with costimulation as signals
1 and 2, such as those stimulated with TLR agonists like Poly-ICLC,
are necessary to induce Th1 and Th2 effector functions and can
force ignorant CD8þ T cells into generating a robust anti-HPV
immune response.Conﬂict of interest
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